Dynavax Technologies Co. (NASDAQ:DVAX) Position Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 1.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,756 shares of the biopharmaceutical company’s stock after selling 1,098 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Dynavax Technologies were worth $744,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVAX. GAMMA Investing LLC boosted its holdings in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 1,685 shares during the period. US Bancorp DE increased its holdings in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new stake in Dynavax Technologies in the 3rd quarter valued at about $45,000. Nisa Investment Advisors LLC boosted its stake in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares during the period. Finally, Algert Global LLC acquired a new position in Dynavax Technologies during the 2nd quarter valued at about $140,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $12.96 on Friday. The firm’s 50-day simple moving average is $11.98 and its 200 day simple moving average is $11.47. The stock has a market cap of $1.70 billion, a P/E ratio of 99.70 and a beta of 1.33. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.01.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.